Market Research Logo

Liquid Biopsy Global Market - Forecast to 2024

Liquid Biopsy Global Market - Forecast to 2024

Liquid biopsy is process of obtaining non-solid tissue usually the blood and other body fluids (urine, saliva etc.) obtained non-invasively as a diagnosis and monitoring tool for disease such as cancer through identification of biomarker in form of cell-fee DNA or circulating tumor cells (CTC) to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up to new possibilities in the field of oncology, transplantation and non-invasive prenatal screening.

According to IQ4I analysis, the liquid biopsy global market is projected to grow at double digit CAGR to reach $8,730.4 million by 2024.

The liquid biopsy market by Biomarkers is segmented into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share of the market & growing at double digit CAGR from 2017-2024. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR from 2017 to 2024.

The applications market is segmented into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application with market which is followed by prenatal testing (NIPT) in 2017, however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at strong CAGR during forecasting period.

The oncology testing market is segmented based on type of cancer into breast cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, ovarian cancer and others, where, breast cancer commanded largest share in 2017, lung cancer is projected to grow at highest CAGR from 2017 to 2024. The oncology testing market is segmented based on cancer care into early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics monitoring market dominates with share in 2017, while early screening is expected to grow at strong CAGR of 22.3% from 2017 to 2024.

The liquid biopsy sample market includes into blood, urine and others where blood dominates the market revenue of $1,881.9 million in 2017 and is expected to maintain the position with strong CAGR growth during forecasting period.

The end-users market is segmented into Hospitals and academic and research institutes. Hospitals attracted the largest revenue in 2017 and are expected to show strong CAGR from 2017 to 2024.

The liquid biopsy geographical market consists of North America, Europe, Asia-Pacific and RoW where North America dominates the market in 2017 followed by Europe. Asia-Pacific market is expected to show highest growth rate during forecasting period.

The report provides an in depth market analysis of the above mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)


1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN AND DATATRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.5 PRIMARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Rising incidence of cancer
3.3.1.2 increasing preference for blood/urine based liquid biopsy over invasive tissue
biopsy procedures
3.3.1.3 rising number of late pregnancies leading to high incidence rate of babies with chromosomal disorders
3.3.1.4 Increasing funding for liquid based test development
3.3.1.5 Technological advancements in liquid biopsy
3.3.1.6 Agreements and collaborations
3.3.1.7 Increasing number of liquid biopsy test launches
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High cost with less reimbursement facilities
3.3.2.2 Ethical issues related to genetic testing
3.3.2.3 Lack of skilled healthcare professionals
3.3.2.4 Lack of standardization of liquid biopsy tests
3.3.2.5 Regulatory issues
3.4 REGULATORY AFFAIRS
3.4.1 U.S.
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 INDIA
3.4.5 JAPAN
3.5 PORTER’S FIVE FORCE ANALYSIS
3.5.1 THREAT OF NEW ENTRANTS
3.5.2 THREAT OF SUBSTITUTES
3.5.3 COMPETITIVE RIVALRY
3.5.4 BARGAINING POWER OF SUPPLIERS
3.5.5 BARGAINING POWER OF BUYERS
3.6 PATENT TRENDS
3.7 MARKET SHARE ANALYSIS
3.8 REIMBURSEMENT SCENARIO
3.9 CLINICAL TRIALS
3.10 TECHNOLOGICAL ADVANCEMENTS
3.10.1 MICRORNA (MIRNA)
3.10.2 PROTEIN BIOMARKERS
3.10.3 CIRCULATING MRNA
3.10.4 CRISPR PAPER TEST (SHERLOCK)
3.11 UPCOMING TESTS
3.12 RESEARCH USE ONLY CELL-FREE DNA TESTS
3.13 FUNDING SCENARIO
3.14 LIQUID BIOPSY COMPANY COMPARISON BY APPLICATIONS
4 MARKET SIZING
4.1 U.S.LIQUID BIOPSY MARKET SIZING INFORMATION
4.1.1 ONCOLOGY TESTING
4.1.1.1 Early screening
4.1.1.2 Companion diagnostics
4.1.1.3 Prognosis monitoring
4.1.1.4 Recurrence monitoring
4.1.2 NON-INVASIVE PRENATAL SCREENING (NIPT)
4.1.3 TRANSPLANTATION DIAGNOSTICS
5 LIQUID BIOPSY GLOBAL MARKET, BY BIOMARKER
5.1 INTRODUCTION
5.2 CIRCULATING TUMOUR CELLS (CTC)
5.3 CELL-FREE DNA (CFDNA)
5.4 EXOSOMES & OTHERS
6 LIQUID BIOPSY GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 ONCOLOGY TESTING
6.2.1 CANCER TYPES
6.2.1.1 Introduction
6.2.1.2 Lung cancer
6.2.1.3 Breast cancer
6.2.1.4 Colorectal cancer
6.2.1.5 Melanoma
6.2.1.6 Prostate cancer
6.2.1.7 Ovarian cancer
6.2.1.8 Others
6.2.2 CANCER CARE
6.2.2.1 Introduction
6.2.2.2 Early screening
6.2.2.3 Companion diagnosis
6.2.2.4 Prognosis monitoring
6.2.2.5 Recurrence monitoring
6.3 PRENATAL TESTING
6.4 TRANSPLANTATION
7 LIQUID BIOPSY GLOBAL MARKET, BY SAMPLE
7.1 INTRODUCTION
7.2 BLOOD
7.3 URINE AND OTHERS
8 LIQUID BIOPSY GLOBAL MARKET, BY END-USERS
8.1 INTRODUCTION
8.2 HOSPITALS
8.3 ACADEMIC & RESEARCH INSTITUTES
9 REGIONAL ANALYSIS
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 UNITED STATES
9.2.2 OTHERS
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 U.K.
9.3.4 OTHERS
9.4 ASIA-PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 OTHERS
9.5 REST OF THE WORLD (ROW)
9.5.1 BRAZIL
9.5.2 REST OF LATIN AMERICA
9.5.3 MIDDLE EAST & OTHERS
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 AGREEMENTS
10.3 COLLABORATIONS/PARTNERSHIPS
10.4 NEW PRODUCT LAUNCHES
10.5 APPROVALS
10.6 ACQUSTIONS
10.7 OTHERS
11 MAJOR COMPANIES
11.1 BGI (BGI DIAGNOSTICS)
11.1.1 OVERVIEW
11.1.2 FINANCIALS
11.1.3 PRODUCTS NIFTY TEST
11.1.4 KEY DEVELOPMENTS
11.1.5 BUSINESS STRATEGY
11.1.6 SWOT ANALYSIS
11.2 BIOCEPT, INC.
11.2.1 OVERVIEW
11.2.2 FINANCIALS
11.2.3 PRODUCT PORTFOLIO
11.2.4 KEY DEVELOPMENTS
11.2.5 BUSINESS STRATEGY
11.2.6 SWOT ANALYSIS
11.3 CAREDX, INC.
11.3.1 OVERVIEW
11.3.2 FINANCIALS
11.3.3 PRODUCT DESCRIPTION
11.3.4 KEY DEVELOPMENTS
11.3.5 BUSINESS STRATEGY
11.3.6 SWOT ANALYSIS
11.4 CYNVENIO BIOSYSTEMS, INC
11.4.1 OVERVIEW
11.4.2 FINANCIALS
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY DEVELOPMENTS
11.4.5 BUSINESS STRATEGY
11.4.6 SWOT ANALYSIS
11.5 EUROFINS SCIENTIFIC SE (LIFECODEXX)
11.5.1 OVERVIEW
11.5.2 FINANCIALS
11.5.3 PRODUCT PORTFOLIO
11.5.4 KEY DEVELOPMENTS
11.5.5 BUSINESS STRATEGY
11.5.6 SWOT ANALYSIS
11.6 EXACT SCIENCES CORPORATION
11.6.1 OVERVIEW
11.6.2 FINANCIALS
11.6.3 PRODUCT PORTFOLIO
11.6.4 KEY DEVELOPMENTS
11.6.5 BUSINESS STRATEGY
11.6.6 SWOT ANALYSIS
11.7 EXOSOME DIAGNOSTICS, INC
11.7.1 OVERVIEW
11.7.2 FINANCIALS
11.7.3 PRODUCT PORTFOLIO
11.7.4 KEY DEVELOPMENTS
11.7.5 BUSINESS STRATEGY
11.7.6 SWOT ANALYSIS
11.8 GUARDANT HEALTH, INC.
11.8.1 OVERVIEW
11.8.2 FINANCIALS
11.8.3 PRODUCT DESCRIPTION
11.8.4 KEY DEVELOPMENTS
11.8.5 BUSINESS STRATEGY
11.8.6 SWOT ANALYSIS
11.9 ILLUMINA, INC.
11.9.1 OVERVIEW
11.9.2 FINANCIALS
11.9.3 PRODUCT PORTFOLIO
11.9.4 KEY DEVELOPMENTS
11.9.5 BUSINESS STRATEGY
11.9.6 SWOT ANALYSIS
11.10 IMMUCOR
11.10.1 OVERVIEW
11.10.2 FINANCIALS
11.10.3 PRODUCT PORTFOLIO
11.10.4 KEY DEVELOPMENTS
11.10.5 BUSINESS STRATEGY
11.10.6 SWOT ANALYSIS
11.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
11.11.1 OVERVIEW
11.11.2 FINANCIALS
11.11.3 PRODUCT PORTFOLIO
11.11.4 KEY DEVELOPMENTS
11.11.5 BUSINESS STRATEGY
11.11.6 SWOT ANALYSIS
11.12 MDX HEALTH
11.12.1 OVERVIEW
11.12.2 FINANCIALS
11.12.3 PRODUCT DESCRIPTION
11.12.4 KEY DEVELOPMENTS
11.12.5 BUSINESS STRATEGY
11.12.6 SWOT ANALYSIS
11.13 MYRIAD GENETICS, INC.
11.13.1 OVERVIEW
11.13.2 FINANCIALS
11.13.3 PRODUCT PORTFOLIO
11.13.4 KEY DEVELOPMENTS
11.13.5 BUSINESS STRATEGY
11.13.6 SWOT ANALYSIS
11.14 NATERA, INC.
11.14.1 OVERVIEW
11.14.2 FINANCIALS
11.14.3 PRODUCT PORTFOLIO
11.14.3.1 PANORAMA
11.14.3.2 CONSTELLATION
11.14.3.3 SIGNATERA
11.14.3.4 VISTARA
11.14.4 KEY DEVELOPMENTS
11.14.5 BUSINESS STRATEGY
11.14.6 SWOT ANALYSIS
11.15 ROCHE HOLDINGS AG
11.15.1 OVERVIEW
11.15.2 FINANCIALS
11.15.3 PRODUCT DESCRIPTION
11.15.4 KEY DEVELOPMENTS
11.15.5 BUSINESS STRATEGY
11.15.6 SWOT ANALYSIS
LIST OF TABLES
LIST OF TABLES
TABLE 1 LIQUID BIOPSY GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 2 LIQUID BIOPSY GLOBAL MARKET REVENUE,
BY BIOMARKERS (2016-2024) ($MN)
TABLE 3 LIQUID BIOPSY GLOBAL MARKET REVENUE,
BY APPLICATIONS, (2016-2024) ($MN)
TABLE 4 LIQUID BIOPSY GLOBAL MARKET REVENUE,
BY SAMPLE (2016-2024) ($MN)
TABLE 5 LIQUID BIOPSY GLOBAL MARKET REVENUE,
BY END-USERS (2016-2024) ($MN)
TABLE 6 ONCOLOGY TESTING U.S. MARKET
TABLE 7 NIPT GLOBAL TOTAL ADDRESSABLE MARKET (TAM)
(HIGH RISK PREGNANCIES) (2017)($MN)
TABLE 8 KIDNEY TRANSPLANTATION DIAGNOSTICS GLOBAL
TOTAL ADDRESSABLE MARKET (TAM) (2017)($MN)
TABLE 9 HEART TRANSPLANTATION DIAGNOSTIS GLOBAL
TOTAL ADDRESSABLE MARKET (TAM) (2017)($MN)
TABLE 10 LIQUID BIOPSY GLOBAL MARKET REVENUE,
BY BIOMARKER (2016-2024) ($MN)
TABLE 11 CIRCULATING TUMOR CELLS GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 12 CELL-FREE DNA GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 13 EXOSOMES & OTHERS GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 14 LIQUID BIOPSY GLOBAL MARKET REVENUE,
BY APPLICATIONS (2016-2024) ($MN)
TABLE 15 ONCOLOGY TESTING GLOBAL MARKET REVENUE,
BY CANCER TYPE (2016-2024) ($MN)
TABLE 16 ONCOLOGY TESTING GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 17 LUNG CANCER GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 18 BREAST CANCER GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 19 COLORECTAL CANCER GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 20 MELANOMA GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
TABLE 21 PROSTATE CANCER GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 22 OVARIAN CANCER GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 23 OTHERS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
TABLE 24 ONCOLOGY TESTING GLOBAL MARKET REVENUE,
BY CANCER CARE (2016-2024) ($MN)
TABLE 25 EARLY SCREENING GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 26 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 27 PROGNOSIS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
TABLE 28 RECURRENCE MONITORING GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 29 PRENATAL (NIPT) TESTING GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 30 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 31 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY SAMPLE (2016-2024) ($MN)
TABLE 32 BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
TABLE 33 URINE & OTHER SAMPLES GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 34 LIQUID BIOPSY GLOBAL MARKET REVENUE,
BY END-USERS,(2016-2024) ($MN)
TABLE 35 HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
TABLE 36 ACADEMIC & RESEARCH INSTITUTES GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
TABLE 37 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
TABLE 38 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN)
TABLE 39 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION (2016-2024) ($MN)
TABLE 40 NORTH AMERICA ONCOLOGY TESTING MARKET REVENUE,
BY CANCER CARE (2016-2024) ($MN)
TABLE 41 NORTH AMERICA ONCOLOGY TESTING MARKET REVENUE,
BY CANCER TYPE (2016-2024) ($MN)
TABLE 42 NORTH AMERCA LIQUID BIOPSY MARKET REVENUE,
BY SAMPLE (2016-2024) ($MN)
TABLE 43 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE,
BY END-USERS, (2016-2024) ($MN)
TABLE 44 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE,
BY COUNTRY, (2016-2024) ($MN)
TABLE 45 EUROPE LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2016-2024) ($MN)
TABLE 46 EUROPE LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
(2016-2024) ($MN)
TABLE 47 EUROPE ONCOLOGY TESTING MARKET REVENUE,
BY CANCER CARE (2016-2024) ($MN)
TABLE 48 EUROPE ONCOLOGY TESTING MARKET REVENUE,
BY CANCER TYPE (2016-2024) ($MN)
TABLE 49 EUROPE LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN)
TABLE 50 EUROPE LIQUID BIOPSY MARKET REVENUE, BY END-USERS,
(2016-2024) ($MN)
TABLE 51 EUROPE LIQUID BIOPSY MARKET REVENUE, BY COUNTRY,
(2016-2024) ($MN)
TABLE 52 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE,
BY BIOMARKERS (2016-2024) ($MN)
TABLE 53 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE,
BY APPLICATION (2016-2024) ($MN)
TABLE 54 ASIA-PACIFIC ONCOLOGY TESTING MARKET REVENUE,
BY CANCER CARE (2016-2024) ($MN)
TABLE 55 ASIA-PACIFIC ONCOLOGY TESTING MARKET REVENUE,
BY CANCER TYPE (2016-2024) ($MN)
TABLE 56 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE,
BY SAMPLE (2016-2024) ($MN)
TABLE 57 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE,
BY END-USERS, (2016-2024) ($MN)
TABLE 58 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE,
BY COUNTRY, (2016-2024) ($MN)
TABLE 59 ROW LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2016-2024) ($MN)
TABLE 60 ROW LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
(2016-2024) ($MN)
TABLE 61 ROW ONCOLOGY TESTING MARKET REVENUE, BY CANCER CARE
(2016-2024) ($MN)
TABLE 62 ROW ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE
(2016-2024) ($MN)
TABLE 63 ROW LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN)
TABLE 64 ROW LIQUID BIOPSY MARKET REVENUE, BY END-USERS
(2016-2024) ($MN)
TABLE 65 ROW LIQUID BIOPSY MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
TABLE 66 AGREEMENTS (2016-2018)
TABLE 67 COLLABORATIONS/PARTNERSHIPS (2016-2018)
TABLE 68 NEW PRODUCT LAUNCH (2016-2018)
TABLE 69 APPROVALS (2016-2018)
TABLE 70 ACQUISITIONS (2016-2018)
TABLE 71 OTHERS (2016-2018)
TABLE 72 BIOCEPT, INC: TOTAL REVENUE AND R&D EXPENSES 2015-2017 ($MN)
TABLE 73 CAREDX, INC.: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
TABLE 74 CAREDX, INC.: TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
TABLE 75 CAREDX, INC.: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
TABLE 76 EUROFINS SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES
(2015-2017) ($MN)
TABLE 77 EUROFINS SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY
(2015-2017) ($MN)
TABLE 78 EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 79 ILLUMINA INC: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
TABLE 80 ILLUMINA INC: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
TABLE 81 ILLUMINA INC: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
TABLE 82 IMMUCOR INC.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 83 IMMUCOR INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 84 IMMUCOR INC.: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
TABLE 85 LABCORP.: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 86 LABCORP.: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
TABLE 87 LABCORP.: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
TABLE 88 MDXHEALTH: TOTAL REVENUE AND R&D EXPENSES,
(2015-2017) ($MN)
TABLE 89 MYRAID GENETICS: TOTAL REVENUE AND R&D EXPENSES,
(2015-2017) ($MN)
TABLE 90 MYRIAD GENETICS, INC.: TOTAL REVENUE, BY SEGMENTS,
(2015-2017) ($MN)
TABLE 91 NATERA, INC.: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 92 NATERA, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
TABLE 93 ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 94 ROCHE HOLDINGS AG: TOTAL REVENUE BY SEGMENTS (2015-2017) ($MN)
TABLE 95 ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES
(2015-2017) ($MN)
TABLE 96 ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY,
(2015-2017) ($MN)
LIST OF FIGURES
LIST OF FIGURES
FIGURE 1 LIQUID BIOPSY GLOBAL MARKET REVENUE & SHARE, BY GEOGRAPHY, (2016-2024) ($MN)
FIGURE 2 LIQUID BIOPSY GLOBAL MARKET: RESEARCH APPROACH
FIGURE 3 LIQUID BIOPSY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 LIQUID BIOPSY GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 LIQUID BIOPSY GLOBAL MARKET: MARKET CRACKDOWN AND
DATA TRIANGULATION
FIGURE 6 LIQUID BIOPSY GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 LIQUID BIOPSY GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 9 LIQUID BIOPSY GLOBAL MARKET: PCT FILING
BY MAJOR PLAYERS (2013-2017)
FIGURE 10 LIQUID BIOPSY MARKET SHARE ANALYSIS BY MAJOR PLAYERS (2017) (%)
FIGURE 11 NIPT MARKET SHARE ANALYSIS BY MAJOR PLAYERS (2017) (%)
FIGURE 12 U.S. LIQUID BIOPSY MARKET: TOTAL ADDRESSABLE MARKET (TAM) ($MN)
FIGURE 13 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY BIOMARKER,
(2017 VS 2024) ($MN)
FIGURE 14 CIRCULATING TUMOR CELLS GLOBAL MARKET REVENUE,
BY REGION (2016-2024) ($MN)
FIGURE 15 CELL-FREE DNA GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 16 EXOSOME & OTHERS DNA GLOBAL MARKET REVENUE,
BY REGION (2017 VS 2024) ($MN)
FIGURE 17 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY APPLICATION,
(2017 VS 2024) ($MN)
FIGURE 18 ONCOLOGY TESTING GLOBAL MARKET SHARE, BY CANCER TYPE
(2017) (%)
FIGURE 19 ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 20 LUNG CANCER GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 21 BREAST CANCER GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 22 COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 23 MELANOMA GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
FIGURE 24 PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 25 OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 26 OTHERS GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
FIGURE 27 EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 28 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 29 PROGNOSIS GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 30 RECURRENCE MONITORING GLOBAL MARKET REVENUE,
BY REGION (2017 VS 2024) ($MN)
FIGURE 31 PRENATAL (NIPT) TESTING GLOBAL MARKET REVENUE,BY REGION
(2017 VS 2024) ($MN)
FIGURE 32 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE,
BY REGION (2017 VS 2024) ($MN)
FIGURE 33 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY SAMPLE,
(2017 VS 2024) ($MN)
FIGURE 34 BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 35 URINE & OTHER SAMPLES GLOBAL MARKET REVENUE, BY REGION
(2017 VS 2024) ($MN)
FIGURE 36 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY END-USERS,
(2017 VS 2024) ($MN)
FIGURE 37 HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
FIGURE 38 ACADEMIC & RESEARCH INSTITUTES GLOBAL MARKET REVENUE,
BY REGION (2017 VS 2024) ($MN)
FIGURE 39 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY GEOGRAPHY,
(2016-2024) ($MN)
FIGURE 40 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
FIGURE 41 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
AND CANCER CARE (2017) ($MN)
FIGURE 42 NORTH AMERICA ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2017) (%) CAGR (%)
FIGURE 43 NORTH AMERICA LIQUID BIOPSY MARKET SHARE, BY SAMPLE
(2017 VS 2024) (%)
FIGURE 44 NORTH AMERICA LIQUID BIOPSY MARKET SHARE, BY END-USERS
(2017 VS 2024) (%)
FIGURE 45 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY COUNTRY
(2017 VS 2024) ($MN)
FIGURE 46 UNITED STATES LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 47 U.S. LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
& TYPE (2017) ($MN)
FIGURE 48 U.S. LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 49 OTHER NORTH AMERICAN COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
FIGURE 50 OTHER NORTH AMERICAN COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
FIGURE 51 OTHER NORTH AMERICAN COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 52 EUROPE LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 53 EUROPE ONCOLOGY TESTING MARKET REVENUE, BY APPLICATION AND CANCER CARE (2017) ($MN)
FIGURE 54 EUROPE ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE
(2017) (%)
FIGURE 55 EUROPE LIQUID BIOPSY MARKET SHARE, BY SAMPLE (2017 VS 2024) (%)
FIGURE 56 EUROPE LIQUID BIOPSY MARKET SHARE, BY END-USERS
(2017 VS 2024) (%)
FIGURE 57 EUROPE LIQUID BIOPSY MARKET REVENUE, BY COUNTRY
(2017 VS 2024) ($MN)
FIGURE 58 GERMANY LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 59 GERMANY LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
FIGURE 60 GERMANY LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 61 FRANCE LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
FIGURE 62 FRANCE LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
& CANCER TYPE (2017) ($MN)
FIGURE 63 FRANCE LIQUID BIOPSY MARKET REVENUE, BY SAMPLE
& BY END-USERS (2017 VS 2024) ($MN)
FIGURE 64 U.K. LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 65 U.K. LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
& CANCER TYPE (2017) ($MN)
FIGURE 66 U.K. LIQUID BIOPSY MARKET REVENUE, BY SAMPLE &
BY END-USERS (2017 VS 2024) ($MN)
FIGURE 67 OTHER EUROPEAN COUNTRIES LIQUID BIOPSY MARKET REVENUE,
BY BIOMARKERS (2017 VS 2024) ($MN)
FIGURE 68 OTHER EUROPEAN COUNTRIES LIQUID BIOPSY MARKET REVENUE,
BY APPLICATION & CANCER TYPE (2017) ($MN)
FIGURE 69 OTHER EUROPEAN COUNTRIES LIQUID BIOPSY MARKET REVENUE,
BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 70 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 71 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
AND CANCER CARE (2017) ($MN)
FIGURE 72 ASIA-PACIFIC ONCOLOGY TESTING MARKET SHARE,
BY CANCER TYPE (2017) (%)
FIGURE 73 ASIA-PACIFIC LIQUID BIOPSY MARKET SHARE, BY SAMPLE
(2017 VS 2024) (%)
FIGURE 74 ASIA-PACIFIC LIQUID BIOPSY MARKET SHARE, BY END-USERS
(2017 VS 2024) (%)
FIGURE 75 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY COUNTRY
(2017 VS 2024) ($MN)
FIGURE 76 JAPAN LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 77 JAPAN LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
& TYPE (2017) ($MN)
FIGURE 78 JAPAN LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 79 CHINA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 80 CHINA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
FIGURE 81 CHINA LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 82 INDIA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 83 INDIA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
& CANCER TYPE (2017) ($MN)
FIGURE 84 INDIA LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 85 OTHER APAC COUNTRIES LIQUID BIOPSY MARKET REVENUE,
BY BIOMARKERS (2017 VS 2024) ($MN)
FIGURE 86 OTHER APAC COUNTRIES LIQUID BIOPSY MARKET REVENUE,
BY APPLICATION & CANCER TYPE (2017) ($MN)
FIGURE 87 OTHER APAC COUNTRIES LIQUID BIOPSY MARKET REVENUE,
BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 88 ROW LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 89 ROW LIQUID BIOPSY MARKET REVENUE, BY APPLICATION
AND CANCER CARE (2017) ($MN)
FIGURE 90 ROW ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2017) (%)
FIGURE 91 ROW LIQUID BIOPSY MARKET SHARE, BY SAMPLE (2017 VS 2024) (%)
FIGURE 92 ROW LIQUID BIOPSY MARKET SHARE, BY END-USERS (2017 VS 2024) (%)
FIGURE 93 ROW LIQUID BIOPSY MARKET REVENUE, BY COUNTRY
(2017 VS 2024) ($MN)
FIGURE 94 BRAZIL LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS
(2017 VS 2024) ($MN)
FIGURE 95 BRAZIL LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
FIGURE 96 BRAZIL LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 97 REST OF LATIN AMERICA LIQUID BIOPSY MARKET REVENUE,
BY BIOMARKERS (2017 VS 2024) ($MN)
FIGURE 98 REST OF LATIN AMERICA LIQUID BIOPSY MARKET REVENUE,
BY APPLICATION & CANCER TYPE (2017) ($MN)
FIGURE 99 REST OF LATIN AMERICA LIQUID BIOPSY MARKET REVENUE,
BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 100 MIDDLE EAST & OTHERS LIQUID BIOPSY MARKET REVENUE,
BY BIOMARKERS (2017 VS 2024) ($MN)
FIGURE 101 MIDDLE EAST & OTHERS LIQUID BIOPSY MARKET REVENUE,
BY APPLICATION & CANCER TYPE (2017) ($MN)
FIGURE 102 MIDDLE EAST & OTHERS LIQUID BIOPSY MARKET REVENUE,
BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
FIGURE 103 KEY GROWTH STRATEGIES, (2016 – 2018)
FIGURE 104 SWOT: BGI
FIGURE 105 SWOT: BIOCEPT, INC.
FIGURE 106 SWOT: CAREDX, INC.
FIGURE 107 SWOT: CYNVENIO BIOSYSTEMS, INC.
FIGURE 108 SWOT: EUROFINS SCIENTIFIC SE
FIGURE 109 SWOT: EXACT SCIENCES CORPORATION
FIGURE 110 SWOT: EXOSOME DIAGNOSTICS
FIGURE 111 SWOT: GUARDANT HEALTH, INC.
FIGURE 112 SWOT: ILLUMINA, INC.
FIGURE 113 SWOT: IMMUCOR, INC.
FIGURE 114 SWOT: LABORATORY CORPORATION OF AMERICA HOLDINGS
FIGURE 115 SWOT: MDXHEALTH
FIGURE 116 SWOT: MYRIAD GENETICS
FIGURE 117 SWOT: NATERA, INC.
FIGURE 118 SWOT: ROCHE HOLDINGS AG

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report